$STIM News

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target

B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5

BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target

NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics Inc (STIM) (Q2 2026) Earnings Call Highlights: Revenue Growth and Margin Expansion ...

Neuronetics Q2 Earnings Call Highlights

Neuronetics Narrows Q2 Loss as Greenbrook Growth Drives 9% Revenue Increase

BTIG Maintains Buy on Neuronetics, Raises Price Target to $6

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

Neuronetics Narrows FY2026 Sales Guidance from $160.000M-$166.000M to $160.000M-$164.000M vs $161.125M Est

Neuronetics Q2 EPS $(0.05) Beats $(0.13) Estimate, Sales $41.568M Beat $40.175M Estimate

Neuronetics and Jorey Chernett Announce Shared Vision

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call